[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasm-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasm-metastases":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,99,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":60,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100355699","phase-1-hsv-g207-in-children-with-recurrent-or-refractory-cerebellar-brain-tumors-100355699",false,"NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* A review of the MRI scan will be necessary to determine if the tumor location and size are such that the patient may be included in the study. The MRI scan must be reviewed and approved by the site neurosurgeon and\u002For study radiologist for enrollment. The following guidelines must be met: Lesion must be ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking. Tumor measurements should be confirmed on the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) form or the institutional MRI report\n* Patients must have fully recovered from acute treatment-related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to the date of G207 administration. All washout intervals below are measured relative to the date of G207 administration.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea) to G207 administration.\n* Monoclonal antibodies: patient must have received the last dose ≥ 21 days prior to G207 administration\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to G207 administration (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥\\>= 7 days).\n* Viral therapy: Patients must have received viral therapy ≥ 3 months prior to G207 administration and must have recovered from all acute toxicities potentially related to the agent\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to G207 administration. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to G207 administration.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to G207 administration.\n* Absolute neutrophil count \\> 1000\u002Fmm3\n* Platelets ≥ 100,000\u002Fmm\\^3\n* Prothrombin time (PT) or partial thromboplastin time (PTT) ≤ 1.3 x control\n* Creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m\\^2 for patients with creatinine levels above institutional normal\n* Total bilirubin ≤ 1.5 mg\u002Fdl\n* Transaminases ≤ 3 times above the upper limits of the institutional norm\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Written informed consent in accordance with institutional and Food and Drug Administration (FDA) guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or central nervous system (CNS) infection ≤ 3 months prior\n* Receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Patient requires an escalation in ongoing systemic corticosteroid therapy within 7 days prior to G207 inoculation or requires ongoing systemic corticosteroid therapy at a dose \\> 2 mg\u002Fday of dexamethasone (or equivalent) at the time of inoculation. For this study, 'systemic corticosteroids' include oral, intravenous, or intramuscular formulations. A single, non-consecutive dose does not constitute exclusion. Physiologic corticosteroid replacement therapy (e.g., hydrocortisone for adrenal insufficiency) is not considered immunosuppressive and does not constitute exclusion\n* Known human immunodeficiency virus (HIV) seropositivity\n* Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone)\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen for this trial\n* Concurrent anticancer or investigational drug","ALL","36 Months","22 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[61,62,28,63,64,65,66,67,68,69,70,71,72,73,74,75,30,76,77,78,79,80,81,82,83,56,55,84,85,86],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","RECRUITING","2026-07-28",{"date":90,"type":91},"2026-07-29","ACTUAL",{"date":93,"type":91},"2019-09-12",{"date":95,"type":21},"2027-09-01",{"name":97,"class":98},"M.D. Anderson Cancer Center","OTHER",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100471487","phase-2-palliative-dose-escalated-radiation-for-painful-non-spine-bone-metastases-and-painful-non-bone-metas-100471487","NCT05419518","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas","Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases","Inclusion Criteria:\n\n* Have provided signed informed consent for the trial\n* Aged ≥18 years at the time of informed consent\n* Histologic proof of malignancy\n* Radiologic or histologic evidence of bone metastases or non-bone metastases\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3\n* Pain Score ≥ 3\n* Life expectancy of six months or more\n* Willing and able to comply with all aspects of the protocol\n* A female participant is eligible to participate if she is not pregnant and not breastfeeding\n* Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n* A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)\n* Spinal metastasis\n* Active compression of spinal cord\u002Fcauda equina\n* Previous RT or SBRT to the same site\n* \\> 3 sites requiring radiation treatment","18 Years",{"count":108,"type":21},124,[110],"PHASE2","The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases",[40,113],"Metastases, Neoplasm",[115,116,117],"Metastase","Bone Neoplasms","Dose Fractionation, Radiation","2026-05-29",{"date":120,"type":91},"2026-06-02",{"date":122,"type":91},"2023-03-16",{"date":124,"type":21},"2027-04-01",{"name":126,"class":98},"Rutgers, The State University of New Jersey",7,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100228066","screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade-100228066","NCT02246634","Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)","Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.","SERENADE","Inclusion Criteria:\n\n1. Have a high risk primary colorectal malignancy\n2. Have a negative CT or includes no confirmatory evidence of liver metastases\n3. Is able to undergo treatment if liver metastasis is found\n4. Have provided written informed consent to participate in the study\n5. Be aged 16 years or over\n\nExclusion Criteria:\n\n1. Have had a previous colorectal malignancy\n2. Have metastatic disease\n3. Have a synchronous second malignancy\n4. Are contraindicated for MRI\n5. Has a T3b or below low rectal tumour without EMVI or N1c","16 Years",{"count":138,"type":21},282,[140],"NA","Eligible patients with high risk colorectal malignancy (T3\u002F4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.\n\nFindings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.",[143,40,144],"Colorectal Neoplasms","Hepatic Neoplasms",[143,40,146,147,144,148,149],"Magnetic Resonance Imaging","Diffusion Weighted MRI","Tumors","Neoplasms, Rectal","2024-10-16",{"date":152,"type":91},"2024-10-17",{"date":154,"type":91},"2014-08",{"date":156,"type":21},"2031-12",{"name":158,"class":98},"Imperial College London",13]